Xcout IntelVeradermics, Incorporated competitors & alternatives
The 12 closest competitors and alternatives to Veradermics, Incorporated among biotechnology companies — ranked by similarity to what Veradermics, Incorporated actually does, not by market-cap band.
Subscribe to see Veradermics, Incorporated’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Veradermics, Incorporated
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Veradermics, Incorporated at a glance
Veradermics, Incorporated is a biotechnology company headquartered in New Haven, United States. It is publicly listed (MANE) with a market capitalisation of $4.6B. Xcout tracks 35 named people at Veradermics, Incorporated, including Reid Waldman (CEO & Director).
Veradermics, Incorporated leadership
- Reid WaldmanCEO & Director
- Dominic CarranoCFO & Treasurer
- Timothy DursoChief Technical Officer
- Tim DursoChief Technical Officer
- Mark NeumannChief Commercial and Strategy Officer
- Michael GrecoGeneral Counsel
29 more named people on record for Veradermics, Incorporated, with roles, board committees and tenure — see the full roster →
Veradermics, Incorporated funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $75M | 11 named |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Veradermics, Incorporated news
- IPOIPO registration (S-1)
- IPOIPO registration (S-1)
- IPONew Haven biotech developing pill for hair loss files for IPO ...
6 corporate events on record, with sources — see the full timeline →
Top 12 Veradermics, Incorporated competitors
Ranked by semantic similarity — how close each company is to Veradermics, Incorporated by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Palvella Therapeutics is a biotechnology company headquartered in Wayne, Pennsylvania, that specializes in developing and commercializing medicines for patients with rare dermatological diseases. The publicly traded company operates with corporate offices and an active team dedicated to clinical and commercial development.
Biotech
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Similar biotechnology company
Amplifica Holdings Group, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing novel treatments for androgenic alopecia.
Biotech
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Similar biotechnology company
Vaderis Therapeutics AG is a clinical-stage biotechnology company focused on developing novel treatments for severe vascular diseases. The company is headquartered in Basel, Switzerland.
Biotech
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.
Similar biotechnology company
Villaris Therapeutics was a clinical-stage biotechnology company developing antibody-based therapies for autoimmune and inflammatory skin diseases. Its intended beneficiaries were patients with immune-mediated dermatologic conditions.
Biotech
NeuroDerm is an R&D company based in Rehovot, Israel, that focuses on healthcare innovation. It integrates pharmaceutical and medical technology solutions to provide patient-centric treatments.
Biotech
Ocean Biomedical, Inc. operates as a biopharmaceutical firm committed to identifying and advancing novel therapeutic solutions for various medical challenges, including cancer, fibrotic disorders, infectious illnesses, and inflammation. The company's pipeline includes the development of both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are specifically designed to target Chi3l1, offering potential treatments for non-small cell lung cancer and glioblastoma multiforme. Additionally, they are progressing a small molecule drug candidate aimed at Chit1, intended to address Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Leveraging its proprietary WPDS platform, Ocean Biomedical is also developing three further product candidates. These encompass a promising malaria vaccine, a humanized mAb therapeutic for malaria that targets the Plasmodium falciparum glutamic-acid-rich protein (PfGARP), and a small molecule malaria therapeutic also designed to interact with PfGARP. Furthermore, a treatment candidate for hospitalized COVID-19 patients is also under development. The company, established in 2019, maintains its operations in Providence, Rhode Island.
Similar biotechnology company
Halda Therapeutics is a life sciences and drug discovery company based in New Haven, Connecticut, focused on developing targeted therapeutics.
Biotech
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
Similar biotechnology company
Eluciderm Inc. is a clinical-stage regenerative medicine small-molecule pharmaceutical company that uses a selective multi-PARP modulation platform to alter the body’s response to inflammation and injury. The company develops therapeutics designed to enable organized tissue regeneration, enhance wound healing, and minimize scarring following trauma.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Veradermics, Incorporated and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Veradermics, Incorporatedand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →